prid delta 1.55 g depotlääkevalmiste, emättimeen
ceva santÉ animale - progesterone - depotlääkevalmiste, emättimeen - 1.55 g - progesteroni
fostimon set 75 iu/ml injektiokuiva-aine ja liuotin, liuosta varten
ibsa farmaceutici italia s.r.l - urofollitropin - injektiokuiva-aine ja liuotin, liuosta varten - 75 iu/ml - urofollitropiini
fostimon set 150 iu/ml injektiokuiva-aine ja liuotin, liuosta varten
ibsa farmaceutici italia s.r.l - urofollitropin - injektiokuiva-aine ja liuotin, liuosta varten - 150 iu/ml - urofollitropiini
pamorelin 11.25 mg injektiokuiva-aine ja liuotin, depotsuspensiota varten
institut produits synthese (ipsen) ab - triptorelin embonate - injektiokuiva-aine ja liuotin, depotsuspensiota varten - 11.25 mg - triptoreliini
pamorelin 22.5 mg injektiokuiva-aine ja liuotin, depotsuspensiota varten
institut produits synthese (ipsen) ab - triptorelin embonate - injektiokuiva-aine ja liuotin, depotsuspensiota varten - 22.5 mg - triptoreliini
suprecur 0.15 mg/annos nenäsumute, liuos
sanofi oy - buserelini acetas - nenäsumute, liuos - 0.15 mg/annos - busereliini
synarela 200 mikrog/annos nenäsumute, liuos
pfizer oy - nafarelin - nenäsumute, liuos - 200 mikrog/annos - nafareliini
firmagon
ferring pharmaceuticals a/s - degareliksia - prostatiset kasvaimet - endokriinihoito - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatiset kasvaimet - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
salvacyl 11.25 mg injektiokuiva-aine ja liuotin, depotsuspensiota varten
institut produits synthese (ipsen) ab - triptorelini embonas - injektiokuiva-aine ja liuotin, depotsuspensiota varten - 11.25 mg - triptoreliini